Biologics CDMO Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Significant is the Anticipated Growth Rate of the Biologics CDMO Market from 2025 to 2034?
The market size of biologics cdmo has been expanding rapidly in recent times. It’s projected to magnify from $21.3 billion in 2024 to $24.37 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.4%. The substantial growth during the historic phase is credited to increased development in biologics, cost-effectiveness as well as flexibility, focus on pivotal competencies, adherence to regulatory requirements, the assurance of quality and the globalization of pharmaceutical supply chains.
Expectations are high for the biologics cdmo market, as it is predicted to experience a swift rise in growth in the forthcoming years. It is projected to reach a value of $42.33 billion by 2029, expanding at a compound annual growth rate (CAGR) of 14.8%. Factors contributing to this growth within the forecast period include a growing demand for biologic therapies, the introduction of biosimilars and biobetters, increased investment in biomanufacturing facilities, a shift towards the outsourcing of complex procedures, focus on strengthening supply chain resiliency and risk reduction, regulatory unification, and expedited approval processes. During the forecast period, key market trends will include broadening capabilities to provide comprehensive solutions, adopting disposable technologies, incorporating continuous manufacturing processes, and the emergence of specialized CDMOs.
How Are the key drivers expanding the growth of the biologics cdmo Market?
The increase in demand for cellular and genetic treatments is anticipated to stimulate the expansion of the biologic CDMO market in the future. Cell and gene therapies are revolutionary medical interventions that employ living cells or genetic substances to tackle the root causes of diseases at the cellular or genetic level, offering potential remedies for conditions that are challenging to treat or incurable with conventional pharmaceuticals. The growing demand for cell and gene therapies is due to their capacity to provide groundbreaking treatments for diseases by tackling the root genetic or cellular causes. Biologic CDMOs are proficient in managing living cells, viral vectors, and genetic substances, ensuring the safe and effective manufacturing of cell and gene therapies while aiding biopharmaceutical firms in overcoming regulatory necessities and technical hurdles, thus easing the transition from research to clinical application. For example, in January 2023, The American Society of Gene & Cell Therapy (ASGCT), a primary professional membership body based in the US, reported that the gene, cell, and RNA therapy pipeline had expanded by 7% in 2022, totaling 3,726 therapies under development. Of these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Hence, the rising demand for cell and genetic therapy is fuelling the expansion of the biologic CDMO market.
Get Your Free Sample of the Global Biologics CDMO Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp
Who Are the Dominant Players Pushing the Boundaries of the Biologics CDMO Market?
Major companies operating in the biologics CDMO market are:
• AbbVie Inc._x000D_
• Thermo Fisher Scientific Inc._x000D_
• Novartis AG_x000D_
• Evonik Industries AG_x000D_
• Sandoz International GmbH_x000D_
How Are Market Trends Revolutionizing the Biologics CDMO Industry in Recent Times?
In the biologics CDMO market, leading firms are focusing on the creation of state-of-the-art solutions, including novel cell lines, to augment their biopharmaceutical creation and manufacturing skills and efficacy. This advanced technology is being used to create therapeutic antibodies with improved strength, tackling obstacles in immunotherapy research and development. As an example, Lonza Group, a Swiss-based firm known for its expertise in the pharmaceutical and biotech fields, rolled out GS Effex cell lines in November 2023. These cell lines are engineered to create antibodies that are completely devoid of the sugar molecule fucose, without compromising on any other performance aspects. The increased potency addresses the challenges in immunotherapy R&D that require enhanced potency of antibody therapeutics. This cell line, which is stable, scalable, and productive, provides a solution for therapeutic development from the early stages of discovery through to commercial production.
Get Instant Access to the Global Biologics CDMO Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report
How Are Key Segments Defining the Competitive Landscape of the Biologics CDMO Market?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Which Geographic Areas Are Influencing the Growth of the Biologics CDMO Market?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can We Define the Biologics CDMO Market and Its Key Components?
A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.
Browse Through More Similar Reports By The Business Research Company:
Privileged Access Management Solutions Global Market Report 2024
Multi-Access Edge Computing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/multi-access-edge-computing-global-market-report
Physical Identity And Access Management Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
